牛牛AI助理已提取核心訊息
Cardio Diagnostics Holdings, Inc., a company specializing in health diagnostics, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on January 26, 2024, will not undergo review by the agency. The SEC's communication, dated January 30, 2024, was addressed to Dr. Meeshanthini Dogan, the Chief Executive Officer of Cardio Diagnostics Holdings. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. Daniel Crawford from the Division of Corporation Finance Office of Life Sciences is the contact person for any further inquiries.
Cardio Diagnostics Holdings, Inc., a company specializing in health diagnostics, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on January 26, 2024, will not undergo review by the agency. The SEC's communication, dated January 30, 2024, was addressed to Dr. Meeshanthini Dogan, the Chief Executive Officer of Cardio Diagnostics Holdings. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. Daniel Crawford from the Division of Corporation Finance Office of Life Sciences is the contact person for any further inquiries.
美國證券交易委員會（SEC）已告知專門從事健康診斷的公司Cardio Diagnostics Holdings, Inc.，其於2024年1月26日提交的S-3表格註冊聲明將不接受該機構的審查。美國證券交易委員會於2024年1月30日發給了Cardio Diagnostics Holdings首席執行官Meeshanthini Dogan博士。美國證券交易委員會的信中還提到了與加快註冊程序的請求有關的第460和461條。此外，美國證券交易委員會提醒該公司及其管理層，無論美國證券交易委員會的審查水平如何，他們都有責任確保披露的準確性和充分性。公司財務部生命科學辦公室的丹尼爾·克勞福德是任何進一步詢問的聯繫人。
美國證券交易委員會（SEC）已告知專門從事健康診斷的公司Cardio Diagnostics Holdings, Inc.，其於2024年1月26日提交的S-3表格註冊聲明將不接受該機構的審查。美國證券交易委員會於2024年1月30日發給了Cardio Diagnostics Holdings首席執行官Meeshanthini Dogan博士。美國證券交易委員會的信中還提到了與加快註冊程序的請求有關的第460和461條。此外，美國證券交易委員會提醒該公司及其管理層，無論美國證券交易委員會的審查水平如何，他們都有責任確保披露的準確性和充分性。公司財務部生命科學辦公室的丹尼爾·克勞福德是任何進一步詢問的聯繫人。
有用
沒用